Indaptus Therapeutics is trading at $2.47, up 9.29% in pre-market, with no fresh company-specific announcement identified to explain the rise.
- Available news listings show earlier company stories, but no October 8 catalyst.
- The broader market is lower, so its direction does not explain the gain.
- Shares fell 12.74% to $2.26 on October 7 before rebounding pre-market; no trading-volume context was provided.